pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals is a pharma organization headquartered in Indianapolis, USA. It trades on NYSE under ticker ACAD. Primary therapeutic focus areas include Schizophrenia, Alzheimer's Disease Psychosis, Parkinson Dis
Indianapolis, USA HQ
17 Employees
Public company Type
ACAD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Indianapolis, USA
- Employees
- 17
- Programs
- 32
- Drugs
- 15
- Patents
- 77
Pimavanserin
Phase 3 · small molecule · Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Pimavanserin for Neuropsychiatric Symptoms Related to Neurodegenerative Disease is a Phase 3 program (small_molecule) at Acadia Pharmaceuticals B.V. with 2 ClinicalTrials.gov record(s).
Internal code ACP-103-046
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Acadia Pharmaceuticals B.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Neuropsychiatric Symptoms Related to Neurodegenerative Disease
- Status
- completed
- Trials
- 2